MelApp - Melanoma Staging vs Melanoma Prognostic Instrument使用状況と統計

Identify rapidly and accurately T, N, M parameters for melanoma staging, guiding you through the complex AJCC tables. Correct staging of melanoma is of fundamental importance for the correct treatment of patients suffering from this condition. In 2018, the eighth edition of the American Joint Committee on Cancer (AJCC) T-N-M classification came into effect to improve the prognostic stratification of melanoma. Calculating the stage of melanoma may not be easy. MelApp is a supporting app that helps you navigate quickly and accurately through the complex AJCC tables. By simply selecting items from a drop-down menu, set according to the criteria of the AJCC tables, MelApp also allows you to identify the three T-N-M parameters. By cross-referencing the three values thus obtained, the final result, parameter S, will help you determine the stage of the lesion as identified by the AJCC tables and suggest possible follow-up indications. MelApp is developed by Meeter Congressi in collaboration with Melanoma Unit - University of Campania "Luigi Vanvitelli", Prof. Giuseppe Argenziano, Dr. Elvira Moscarella, Dr. Gabriella Brancaccio and Dr. Teresa Russo. Meeter Congressi and Melanoma Unit have developed MelApp based on the information contained in the AJCC Cancer Staging Manual. The definitions used are copyrighted by AJCC. We are not responsible for the academic accuracy or thoroughness of the information contained in the AJCC Cancer Staging Manual. Meeter Congressi and Melanoma Unit shall not be held liable for any damages arising out of the use of the information contained in MelApp, for any injury or damage to persons or property resulting from the use of the app or any of its features, including lost profits, punitive or exemplary damages, since it serves only as guidance support for the AJCC tables. MelApp is an entertainment tool for health care worker education and is not a diagnostic and therapeutic resource. MelApp is not a medical device. MelApp should not be used for the diagnosis or treatment of melanoma. Only a doctor can diagnose or treat melanoma. Possible follow-up indications are for guidance only. Only a doctor can diagnose or treat melanoma. MelApp is not intended to replace the results of the patient's medical history and objective examination.
  • Apple App ストア
  • 無料
  • 医学

ストアランキング

- -

The Prognostic Instrument for Melanoma (version 2.0) is a population-based tool that is based on a large amount of clinical and histopathological data from the Swedish quality registry for cutaneous melanoma (SweMR). In this updated version of the instrument, data from more than 70,000 patients with primary malignant melanoma between 1990 and 2021 have been included. Through a combination of several independent risk factors, melanoma-specific survival has been analysed for a variety of risk groups. The instrument calculates survival 1 to 10 years after diagnosis and provides an analysis at group level but can never provide an exact individual prognosis. The results are presented with 95% confidence intervals. The prognostic instrument has been designed for use by physicians in relation to patients with primary malignant melanoma. The analyses that form the basis of the instrument are performed on separate models for thin melanomas (≤ 1mm) and thicker melanomas (> 1mm) due to the fact that sentinel lymph node biopsy (SLNB) is generally not recommended for thin melanomas in Sweden. When choosing a thickness of 1 mm or less in the instrument, "Sentinel lymph node status" will not be included as a parameter.
  • Apple App ストア
  • 無料
  • 医学

ストアランキング

- -

MelApp - Melanoma Staging対Melanoma Prognostic Instrumentランキング比較

と過去28日間の MelApp - Melanoma Staging ランキング傾向を比較 Melanoma Prognostic Instrument

ランキング

ご利用可能なデータがありません

MelApp - Melanoma Staging 対 Melanoma Prognostic Instrument 国の比較によるランキング

と過去28日間の MelApp - Melanoma Staging ランキング傾向を比較 Melanoma Prognostic Instrument

表示できるデータはありません

無料トライアルで任意のサイトと比較する

始める
MelApp - Melanoma Staging VS.
Melanoma Prognostic Instrument

12月 19, 2024